These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8305410)

  • 21. Phenotypic effects of apolipoprotein structural variation on lipid profiles. III. Contribution of apolipoprotein E phenotype to prediction of total cholesterol, apolipoprotein B, and low density lipoprotein cholesterol in the healthy women study.
    Eichner JE; Kuller LH; Ferrell RE; Meilahn EN; Kamboh MI
    Arteriosclerosis; 1990; 10(3):379-85. PubMed ID: 2344296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of apolipoprotein E genotype on the reliability of the Friedewald formula in the estimation of low-density lipoprotein cholesterol concentrations.
    Tremblay AJ; Bergeron J; Gagné JM; Gagné C; Couture P
    Metabolism; 2005 Aug; 54(8):1014-9. PubMed ID: 16092050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of defective binding of low density lipoprotein by the U937 proliferation assay in German patients with familial defective apolipoprotein B-100.
    Schewe CK; Schuster H; Hailer S; Wolfram G; Keller C; Zöllner N
    Eur J Clin Invest; 1994 Jan; 24(1):36-41. PubMed ID: 8187806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Familial defective apolipoprotein B100: clinical characteristics of 54 cases.
    Rauh G; Keller C; Kormann B; Spengel F; Schuster H; Wolfram G; Zöllner N
    Atherosclerosis; 1992 Feb; 92(2-3):233-41. PubMed ID: 1632851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Compound heterozygous familial hypercholesterolemia and familial defective apolipoprotein B-100 produce exaggerated hypercholesterolemia.
    Tai ES; Koay ES; Chan E; Seng TJ; Loh LM; Sethi SK; Tan CE
    Clin Chem; 2001 Mar; 47(3):438-43. PubMed ID: 11238294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased clearance of low density lipoprotein precursors in patients with heterozygous familial defective apolipoprotein B-100: a stable isotope approach.
    Pietzsch J; Wiedemann B; Julius U; Nitzsche S; Gehrisch S; Bergmann S; Leonhardt W; Jaross W; Hanefeld M
    J Lipid Res; 1996 Oct; 37(10):2074-87. PubMed ID: 8906585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia.
    Myant NB
    Atherosclerosis; 1993 Dec; 104(1-2):1-18. PubMed ID: 8141833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apolipoprotein E genotypes and metabolic risk factors for coronary heart disease in middle-aged women.
    Cubrilo-Turek M; Stavljenić-Rukavina A; Sertić J; Zrinski R; Turek S; Grgac G; Ljubojević N
    Coll Antropol; 1998 Jun; 22(1):149-55. PubMed ID: 10097431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Familial ligand-defective apolipoprotein B-100: detection, biochemical features and haplotype analysis of the R3531C mutation in the UK.
    Wenham PR; Henderson BG; Penney MD; Ashby JP; Rae PW; Walker SW
    Atherosclerosis; 1997 Mar; 129(2):185-92. PubMed ID: 9105560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. R3531C mutation in the apolipoprotein B gene is not sufficient to cause hypercholesterolemia.
    Rabès JP; Varret M; Devillers M; Aegerter P; Villéger L; Krempf M; Junien C; Boileau C
    Arterioscler Thromb Vasc Biol; 2000 Oct; 20(10):E76-82. PubMed ID: 11031227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of a heterozygous compound individual with familial hypercholesterolemia and familial defective apolipoprotein B-100.
    Rauh G; Schuster H; Fischer J; Keller C; Wolfram G; Zöllner N
    Klin Wochenschr; 1991 May; 69(7):320-4. PubMed ID: 2067318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rare and common mutations in hyperlipidemia and atherosclerosis. With special reference to familial defective apolipoprotein B-100.
    Tybjaerg-Hansen A
    Scand J Clin Lab Invest Suppl; 1995; 220():57-76. PubMed ID: 7652481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Flow cytometric assessment of LDL ligand function for detection of heterozygous familial defective apolipoprotein B-100.
    Raungaard B; Heath F; Hansen PS; Brorholt-Petersen JU; Jensen HK; Faergeman O
    Clin Chem; 2000 Feb; 46(2):224-33. PubMed ID: 10657378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Identification and characterization of the first Spanish familial ligand-defective apolipoprotein B homozygote].
    Ejarque I; Civer M; Francisco Ascaso J; Knecht E; Eugenia Armengod M; Carmen R; Tomás Real J; Francisco Chaves J; Javier Martín De Llano J
    Med Clin (Barc); 2001 Feb; 116(4):138-41. PubMed ID: 11222161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The binding of very low density lipoprotein remnants to the low density lipoprotein receptor in familial defective apolipoprotein B-100.
    Maher VM; Gallagher JJ; Myant NB
    Atherosclerosis; 1993 Aug; 102(1):51-61. PubMed ID: 8257452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Familial defective apolipoprotein B versus familial hypercholesterolemia: an assessment of risk.
    Fouchier SW; Defesche JC; Kastelein JJ; Sijbrands EJ
    Semin Vasc Med; 2004 Aug; 4(3):259-64. PubMed ID: 15630635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Familial defective apolipoprotein B-100: haplotype analysis of the arginine(3500)----glutamine mutation.
    Rauh G; Schuster H; Fischer J; Keller C; Wolfram G; Zöllner N
    Atherosclerosis; 1991 Jun; 88(2-3):219-26. PubMed ID: 1892487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypocholesterolemic effects of cholestyramine and colestipol in patients with familial defective apolipoprotein B-100.
    Schmidt EB; Illingworth DR; Bacon S; Mahley RW; Weisgraber KH
    Atherosclerosis; 1993 Jan; 98(2):213-7. PubMed ID: 8457260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does the presence of the 3500 mutant apolipoprotein B-100 in low density lipoprotein particles affect their atherogenicity?
    Maher VM; Gallagher JJ; Thompson GR; Myant NB
    Atherosclerosis; 1995 Nov; 118(1):105-10. PubMed ID: 8579620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of the apo B-3500 mutation in the Norwegian population.
    Leren TP; Rødningen OK; Tonstad S; Røsby O; Urdal P; Ose L
    Scand J Clin Lab Invest; 1995 May; 55(3):217-21. PubMed ID: 7638555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.